These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18299967)

  • 1. An alternative method for population pharmacokinetic data analysis under noncompliance.
    Gupta P; Hutmacher MM; Frame B; Miller R
    J Pharmacokinet Pharmacodyn; 2008 Apr; 35(2):219-33. PubMed ID: 18299967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.
    Lu J; Gries JM; Verotta D; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2001 Aug; 28(4):343-62. PubMed ID: 11677931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches to handling pharmacodynamic baseline responses.
    Dansirikul C; Silber HE; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):269-83. PubMed ID: 18446428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Handling Missing Dosing History in Population Pharmacokinetic Modeling: An Extension to MDM Method.
    Wang Y; Liu X
    CPT Pharmacometrics Syst Pharmacol; 2019 Jan; 8(1):39-49. PubMed ID: 30536631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population one-compartment pharmacokinetic analysis with missing dosage data.
    Soy D; Beal SL; Sheiner LB
    Clin Pharmacol Ther; 2004 Nov; 76(5):441-51. PubMed ID: 15536459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical power in randomized intervention studies with noncompliance.
    Jo B
    Psychol Methods; 2002 Jun; 7(2):178-93. PubMed ID: 12090409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models.
    Xu XS; Dunne A; Kimko H; Nandy P; Vermeulen A
    J Pharmacokinet Pharmacodyn; 2011 Aug; 38(4):423-32. PubMed ID: 21626437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
    Mu S; Ludden TM
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.
    Knights J; Rohatagi S
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):627-37. PubMed ID: 26209956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of different population pharmacokinetic algorithms.
    Colucci P; Grenier J; Yue CS; Turgeon J; Ducharme MP
    Ther Drug Monit; 2011 Oct; 33(5):583-91. PubMed ID: 21912327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.
    Jacqmin P; Snoeck E; van Schaick EA; Gieschke R; Pillai P; Steimer JL; Girard P
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):57-85. PubMed ID: 17051439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
    Proost JH; Schiere S; Eleveld DJ; Wierda JM
    Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
    Zhang L; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data.
    Tunblad K; Lindbom L; McFadyen L; Jonsson EN; Marshall S; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):503-26. PubMed ID: 19011957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Handling data below the limit of quantification in mixed effect models.
    Bergstrand M; Karlsson MO
    AAPS J; 2009 Jun; 11(2):371-80. PubMed ID: 19452283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing convergence of Markov chain Monte Carlo simulations in hierarchical Bayesian models for population pharmacokinetics.
    Dodds MG; Vicini P
    Ann Biomed Eng; 2004 Sep; 32(9):1300-13. PubMed ID: 15493516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Causal inference in a clinical trial: a comparative example.
    Heitjan DF
    Control Clin Trials; 1999 Aug; 20(4):309-18. PubMed ID: 10440558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic parameters estimation using adaptive Bayesian P-splines models.
    Jullion A; Lambert P; Beck B; Vandenhende F
    Pharm Stat; 2009; 8(2):98-112. PubMed ID: 18481279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.